FY2028 Earnings Forecast for BIO Issued By Zacks Research

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Analysts at Zacks Research issued their FY2028 EPS estimates for shares of Bio-Rad Laboratories in a research report issued to clients and investors on Monday, March 2nd. Zacks Research analyst Team forecasts that the medical research company will post earnings of $9.87 per share for the year. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The business had revenue of $693.20 million for the quarter, compared to analysts’ expectations of $694.64 million. During the same quarter last year, the business posted $2.90 earnings per share. The business’s revenue was up 3.9% compared to the same quarter last year.

A number of other equities research analysts have also issued reports on BIO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bio-Rad Laboratories presently has an average rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Trading Up 0.4%

Shares of BIO opened at $280.73 on Wednesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.62 and a quick ratio of 4.19. The firm has a 50 day simple moving average of $297.25 and a 200-day simple moving average of $301.46. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $343.12. The stock has a market cap of $7.58 billion, a price-to-earnings ratio of 10.06 and a beta of 1.18.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several hedge funds have recently made changes to their positions in BIO. Virtu Financial LLC acquired a new position in Bio-Rad Laboratories in the fourth quarter valued at $672,000. Corient Private Wealth LLC increased its stake in shares of Bio-Rad Laboratories by 4,570.8% during the 4th quarter. Corient Private Wealth LLC now owns 66,792 shares of the medical research company’s stock valued at $20,237,000 after acquiring an additional 65,362 shares during the last quarter. Vident Advisory LLC purchased a new position in shares of Bio-Rad Laboratories during the 4th quarter worth about $892,000. State of Tennessee Department of Treasury lifted its holdings in shares of Bio-Rad Laboratories by 35.1% during the 4th quarter. State of Tennessee Department of Treasury now owns 3,796 shares of the medical research company’s stock worth $1,115,000 after acquiring an additional 987 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its position in shares of Bio-Rad Laboratories by 9.1% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 259,577 shares of the medical research company’s stock worth $78,649,000 after acquiring an additional 21,674 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Key Headlines Impacting Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Zacks raised its Q1 2027 EPS estimate to $2.22 from $2.12 — a rare upward revision in the package that could be viewed as a near‑term positive for the company’s coming quarter.
• Neutral Sentiment: Zacks trimmed Q4 2026 to $2.59 from $2.60 and Q2 2026 to $2.34 from $2.35; FY2026 was nudged to $10.32 from $10.36. These changes are very small and likely have limited immediate impact on valuation.
• Negative Sentiment: Zacks lowered several forward estimates more meaningfully: FY2027 EPS to $9.30 (from $9.38), Q2 2027 to $2.30 (from $2.44), Q3 2027 to $2.35 (from $2.39) and Q1 2026 to $2.77 (from $2.79). It also published a FY2028 estimate of $9.87, well below the street consensus near $10.81 — signaling a weaker medium‑term earnings trajectory that could pressure the stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.